Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.38 |
| ▸ | F10 | P00742 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924782 | 0.85 | COMT (0.46) | F2F10MAPTLMNATP53 | |
| SCHEMBL2471712 | 0.84 | RAB9A (0.38) | F2F10MAPTTHRBPOLB | |
| SCHEMBL14924785 | 0.82 | PTGS2 (0.48) | MAPTLMNATP53POLB | |
| SCHEMBL14924784 | 0.75 | LMNA (0.39) | F2F10MAPTLMNATP53 | |
| SCHEMBL14924749 | 0.74 | ALDH1A1 (0.33) | MAPTLMNATP53RAPGEF4 | |
| SCHEMBL14924766 | 0.74 | F2 (0.47) | F2F10MAPTLMNAGAA | |
| SCHEMBL2473827 | 0.73 | F2 (0.41) | F2F10MAPTTHRBPOLB | |
| SCHEMBL3050480 | 0.72 | TAAR1 (0.38) | F2F10MAPT | |
| SCHEMBL31618496 | 0.72 | TRIM24 (0.39) | MAPTGAA | |
| SCHEMBL2473536 | 0.72 | F2 (0.48) | F2F10MAPTLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802860-B2 | Method for producing substituted pyridin-2-one | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20130116443-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116443-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | PNPO, CYP4B1, DPYD | F2 2310/4885F10 4145/4885MAPT 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.